The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
申请公布号
WO2015011119(A2)
申请公布日期
2015.01.29
申请号
WO2014EP65674
申请日期
2014.07.22
申请人
BASF SE
发明人
HAFNER, ANDREAS;BLATTER, FRITZ;SZELAGIEWICZ, MARTIN;SIEBENHAAR, BERND;CHIODO, TIZIANA;HINTERMANN, TOBIAS;SALVADOR, BEATE;VOSSEN, MARCUS